1 June 2016 - NICE has published a second appraisal consultation document for ibrutinib for chronic lymphocytic leukaemia.

Ibrutinib is not recommended for treating chronic lymphocytic leukaemia in adults without a 17p deletion or TP53 mutation.

The committee has invited Janssen-Cilag to submit a proposal for inclusion in the Cancer Drugs Fund.

The committee will consider ibrutinib for the third time in early August.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/gid-tag492/consultation/html-content-2